Pharvaris (NASDAQ:PHVS) Posts Earnings Results, Beats Estimates By $0.19 EPS

Pharvaris (NASDAQ:PHVSGet Rating) posted its quarterly earnings results on Monday. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.19, MarketWatch Earnings reports.

Pharvaris Stock Up 2.0 %

PHVS traded up $0.18 during trading on Wednesday, reaching $9.25. 1 shares of the company were exchanged, compared to its average volume of 15,400. Pharvaris has a 12-month low of $8.55 and a 12-month high of $27.50. The company’s 50-day moving average is $17.03 and its two-hundred day moving average is $18.05. The company has a market cap of $294.52 million, a price-to-earnings ratio of -3.56 and a beta of -0.19.

Institutional Trading of Pharvaris

An institutional investor recently raised its position in Pharvaris stock. Bank of America Corp DE raised its position in shares of Pharvaris (NASDAQ:PHVSGet Rating) by 1,054.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,772 shares of the company’s stock after purchasing an additional 5,272 shares during the period. Bank of America Corp DE’s holdings in Pharvaris were worth $105,000 at the end of the most recent reporting period. 70.21% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on PHVS. Morgan Stanley cut shares of Pharvaris from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $40.00 to $10.00 in a research note on Tuesday, August 23rd. JMP Securities reduced their price objective on Pharvaris from $34.00 to $18.00 and set a “mkt outperform” rating for the company in a report on Tuesday. Bank of America lowered Pharvaris from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $26.00 to $13.00 in a research note on Monday, August 22nd. Oppenheimer cut their price target on Pharvaris from $48.00 to $22.00 and set an “outperform” rating for the company in a research note on Tuesday, August 23rd. Finally, SVB Leerink lowered their price objective on Pharvaris from $25.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $16.60.

About Pharvaris

(Get Rating)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).

Further Reading

Earnings History for Pharvaris (NASDAQ:PHVS)

Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.